The Global Emerging Markets Group (GEM)

GEM Portfolio Company, The Catholic Herald announces new equity investment from Patrick Gruhn, LL.M., MBA, a European entrepreneur in media, technology, and finance. - As part of the investment, Patrick Gruhn will join the Board of Directors. The agreement also grants rights to syndicate The Catholic Herald’s 137-year content archive across Germany, Austria, Switzerland, and Liechtenstein. - Patrick Gruhn is an accomplished entrepreneur, lawyer, software engineer, and fintech innovator with a career spanning Europe and the United States. He has deep expertise in blockchain technology, artificial intelligence, regulatory frameworks, and financial markets, having built and led ventures across IT, digital assets, and financial infrastructure. https://lnkd.in/gz-xAqmB

GEM Portfolio Company, Turn Therapeutics ("TTRX") Completes Direct Listing on NASDAQ - About Turn Therapeutics Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation. https://lnkd.in/gBEbiC3M

GEM commits $120m to Kensana Health ahead of NASDAQ Listing - About Kensana Kensana, is a Canadian Phytopharmaceutical company that has created a proprietary Generation 4 AI-enhanced phytobioreactor platform (EMOB) which enables the company to assume leadership in a new industry: Phytopharmaceuticals. The EMOB platform allows Kensana to standardize and convert an abundance of naturally occurring plant and compounds into U.S. FDA registered pharmaceuticals with global respectability. Kensana’s first patented formula is entering an international FDA-registerable Phase 3 clinical trial. Uniquely risk-mitigated, the KV23a formula has already successfully proven safety and efficacy via therapeutic applications in a clinical setting. KV23a is Kensana’s first targeted FDA- registered product within a global chronic wound market worth $300 Billion USD. The Patented Chronic Wound Formula, KV23a, has Proven Medical Efficacy which has been demonstrated in Published peer reviewed medical journals validating KV23a and its efficacy while demonstrating no toxicity issues. Phytopharmaceuticals largely work by targeting specific receptors, interrupting disease pathways and disrupting pathogenic life cycles. The Kensana Platform, EMOB, has the ability to produce proprietary therapies as well as re-engineer synthetic drugs originally derived from natural plant compounds. Kensana Health has a uniquely risk-mitigated business model and is currently entering a Series C Investment Round. For more information, please visit the website at www.kensana.health or contact Randy Uens at Randy@Kensana.health. https://lnkd.in/gwxm2h6f